- Status Complete
- Type New application
- Pre-PASC consultation Not applicable
- Pre-MSAC consultation Closed
- Outcome Not supported
Application details
Reason for application
Highly specialised therapy – National Health Reform Agreement.
Service or technology in this application
Brexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.
Type: Therapeutic technology
Medical condition this application addresses
Acute lymphoblastic leukaemia is a blood cancer that appears suddenly and grows rapidly. It starts when immature white blood cells called blasts become cancerous.
Application documents
Application form
Consultation survey
Public summary document
Public summary document
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Consultation survey and deadlines
- PASC consultation: Expedited – bypassed PASC
- MSAC consultation: Closed Friday 7 October 2022
Meetings to consider this application
- PASC meeting: Expedited – bypassed PASC
- ESC meeting: 6–7 October 2022
- MSAC meeting: 24–25 November 2022